Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.

British journal of clinical pharmacology - 1 Oct 1999

Brynne N, Forslund C, Hallén B, Gustafsson L L, Bertilsson L

Abstract excerpt

AIMS: To investigate the pharmacokinetics and safety of tolterodine and tolterodine metabolites after single-and multiple-dose administration in the absence and presence of ketoconazole, an inhibitor of cytochrome P450 (CYP) 3A4, in healthy volunteers with deficient CYP2D6 activity, i.e. poor metabolisers of debrisoquine. METHODS: Eight healthy volunteers received single oral doses (2 mg) of tolterodine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzhydryl Compounds
Share to Cresols
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Drug Interactions

Share to Mixed Function Oxygenases

Share to Muscarinic Antagonists

Source

Open in PubMed Open full text

Identifiers

PMID: 10583027
DOI: 10.1046/j.1365-2125.1999.00053.x
PMCID: PMC2014365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.PMID 10583027Read ↗

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.Semantic proximity Read ↗

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.Semantic proximity Read ↗

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.Semantic proximity Read ↗

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.Semantic proximity Read ↗

Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.Semantic proximity Read ↗

Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.Semantic proximity Read ↗

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its MechanismSemantic proximity Read ↗

Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.Semantic proximity Read ↗

Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.Semantic proximity Read ↗

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.Semantic proximity Read ↗

Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.